Picture Berlin Partner Hotspot for Startups 650x80px
Organisation › Details

Oryzon Genomics (Group)

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with Roche. Oryzon’s LSD1 program is currently covered by + 20 patent families and has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon’s strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts. *


Period Start 2000-06-02 established
Products Industry LSD1 inhibitor (Lysine Specific Demethylase-1 inhibitor)
  Industry 2 ORY-1001 (RG6016) (Oryzon/Roche)
Persons Person Buesa, Carlos (Oryzon Genomics SA 201404 CEO + Co-Founder)
  Person 2 Rello, Enric (Oryzon Genomics 201605 CFO)
Region Region Madrid
  Country Spain (España)
  Street 15 Carrera de San Jerónimo
2nd Floor
  City Madrid
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for �About Section�: Oryzon Genomics S.A.. (5/16/17). "Press Release: Oryzon Announces Appointment of New Chief Medical Officer and Expansion of Its Medical Department". Barcelona & Cambridge, MA.
Record changed: 2019-05-30


Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Oryzon Genomics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC A October 650x80px

» top